A Systematic Literature Review of Economic Evaluations and Cost Studies of the Treatment of Psoriasis, Atopic Dermatitis, and Chronic Urticaria,Dermatology and Therapy

当前位置： X-MOL 学术 › Dermatol. Ther. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

A Systematic Literature Review of Economic Evaluations and Cost Studies of the Treatment of Psoriasis, Atopic Dermatitis, and Chronic Urticaria
Dermatology and Therapy ( IF 3.5 ) Pub Date : 2022-07-31 , DOI: 10.1007/s13555-022-00774-2
Atsuyuki Igarashi ₁ , Akira Yuasa ₂ , Naohiro Yonemoto ₂ , Kazumasa Kamei ₂ , Michael LoPresti ₃ , Toshiaki Murofushi ₃ , Shunya Ikeda ₄

Affiliation

Introduction

Psoriasis (PSO), atopic dermatitis (AD), and chronic urticaria (CU) are common manifestations of immunological skin and subcutaneous conditions and have been shown to have a substantial impact on the quality of life of patients. The cost of treating those conditions can also be high, as the use of biologic treatments has become more common for moderate to severe patients. In this review, we examine characteristics of economic evaluations and cost studies conducted for the three conditions.

Methods

A literature search was conducted using PubMed, Embase, and the Cochrane Library from January 1, 2016 to October 26, 2020 to identify economic evaluations where the cost of one or more drug treatment was evaluated and cost studies covering any intervention type. Each database was searched using keyword and MeSH terms related to treatment costs (e.g., health care cost, drug cost, etc.) and each condition (e.g., PSO, AD, eczema, CU, etc.).

Results

A total of 123 studies were reviewed, including 104 studies (85%) of PSO (including psoriasis, plaque psoriasis, psoriatic arthritis, and psoriasis vulgaris), 14 studies (11%) of AD, and 5 studies (4%) of CU. Seventy-two studies (59%) reviewed reported the inclusion of biologic treatments, 10 studies (8%) did not include biologic treatments, and 41 studies (33%) did not report whether or not a biologic treatment was included. While nearly all studies (98%) included direct costs, only 22 studies (18%) included indirect costs.

Conclusions

Economic evaluations for AD and CU may be needed in order to better understand the value of new treatments. Moreover, a clearer delineation for biologic treatments and indirect costs (i.e., productivity losses and gains) may be required.

中文翻译：

银屑病、特应性皮炎和慢性荨麻疹治疗的经济评估和成本研究的系统文献综述

介绍

银屑病 (PSO)、特应性皮炎 (AD) 和慢性荨麻疹 (CU) 是免疫性皮肤和皮下疾病的常见表现，已被证明对患者的生活质量产生重大影响。治疗这些疾病的成本也可能很高，因为对于中度至重度患者来说，生物治疗的使用变得越来越普遍。在这篇综述中，我们研究了针对这三种情况进行的经济评估和成本研究的特征。

方法

使用 PubMed、Embase 和 Cochrane 图书馆于 2016 年 1 月 1 日至 2020 年 10 月 26 日进行文献检索，以确定对一种或多种药物治疗的成本进行评估的经济评估以及涵盖任何干预类型的成本研究。使用与治疗成本（例如，医疗保健成本、药物成本等）和每种病症（例如，PSO、AD、湿疹、CU 等）相关的关键词和 MeSH 术语搜索每个数据库。

结果

总共回顾了 123 项研究，包括 104 项（85%）PSO（包括银屑病、斑块状银屑病、银屑病关节炎和寻常型银屑病）研究、14 项 AD（AD）研究（11%）和 5 项 CU（CU）研究（4%）。 72 项研究 (59%) 报告了生物治疗的纳入，10 项研究 (8%) 未纳入生物治疗，41 项研究 (33%) 未报告是否纳入生物治疗。虽然几乎所有研究 (98%) 都包含直接成本，但只有 22 项研究 (18%) 包含间接成本。